inositol-requiring enzyme-1 (IRE-1), a Ser/Thr kinase with an endonuclease domain that can remove 26-nucleotides from the mRNA of x-box binding protein 1 (XBP-1), resulting in the translation of stable XBP-1 transcription factor to promote ER stress gene program; and the type II transmembrane protein or the activating transcription factor-6 (ATF-6), which can facilitate the ER folding capacity through induction of chaperone expression. Although the importance of these pathways has been recognized, there are only a few studies of their functional significance in the intact heart. Specifically, the role of ATF-6 has been addressed in cardiac ischemic injury, 9, 10 but the roles of PERK or IRE-1 have not been delineated. Although the ER stress response is initially directed toward cellular adaptation to alleviate the unfolded protein load, prolonged ER stress is associated with activation of apoptosis. In this regard, the kinase domain of IRE-1 was reported to activate c-Jun N-terminal kinase by interacting with tumor necrosis factor receptor-associated factor 2 and apoptosis signal-regulating kinase 1 in neuronal and pancreatic tumor cell lines. 11, 12 The IRE-1/tumor necrosis factor receptor-associated factor 2 complex also contributes to apoptosis through caspase 12 released from the ER and the ensuing cell death. 13 The anti-apoptotic HS-1-associated protein X-1 (HAX-1) may be a new regulator of ER-mediated cell survival. HAX-1 is ≈35-kDa protein, which was originally found to form a complex with HS-1 (hematopoietic lineage substrate-1) in lymphocytes, and to mediate lymphocyte differentiation. 14 In vitro studies provided the first experimental evidence that HAX-1 protects against cell death, 15 such as promotion of cardiomyocyte survival through caspase-9 inhibition on hydrogen peroxide treatment. 16 Its protective role against cell death in vivo subsequently was demonstrated in a global genetic deletion mouse, which had a short lifespan because of progressive loss of neuronal cells. 17 More importantly, human mutations were found in the HAX-1 gene, which can result in loss of this protein, and the affected individuals present with severe neutropenia, a rare immunodeficiency disease with scarce neutrophil counts. 15 However, although HAX-1 has been reported to regulate cell survival in multiple tissues, 15 its potential protective role in cardiac muscle is virtually unknown. HAX-1 has been shown to be present in both the mitochondria and the SR and to associate with phospholamban (PLN), regulating cardiac calcium homeostasis. 18 Given the regulatory role of HAX-1 in calcium cycling and its anti-apoptotic properties in other tissues, it becomes important to delineate the functional role of HAX-1 in the stressed heart because this may reveal novel insights for potential therapeutic interventions.
Here, we demonstrate for the first time that HAX-1 reduces cardiac infarct size and improves contractile recovery after I/R ex vivo and in vivo. The protective effects of HAX-1 are mediated by formation of a regulatory complex between HAX-1 and heat shock protein 90 (Hsp90), resulting in inhibition of ER stress-induced cell death response through the IRE-1 signaling pathway. Moreover, the HAX-1/Hsp90 complex is recruited to PLN-sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) 2a, suggesting a "functional coupling" between ER stress signaling elements and calcium homeostasis in cardiac myocytes. Thus, HAX-1 protection may be partially mediated at the ER/SR level, promoting cell survival against noxious conditions such as I/R injury.
Methods
Detailed Methods are available in the Online Supplement, which includes the description of animal models, ex vivo global I/R, in vivo regional ischemia, rat myocytes isolation and virus infection, mouse cardiomyocyte isolation and calcium kinetics measurement, cardiomyocyte apoptosis treatment and Annexin V staining, Western blot analysis, caspase-3 and calpain activities measurement, DNA fragmentation measurement, terminal dUTP nick-end labeling assays, plasma troponin I measurement, quantitative real-time polymerase chain reaction assay, generation of recombinant protein and blot overlay assay, glutathione-S-transferase (GST) pull-down assay, competitive protein binding enzyme-linked immunosorbent assay, coimmunoprecipitation, immunofluorescence staining, and statistical analysis.
Results

HAX-1 Protects Hearts From I/R Injury
I/R injury can tilt the balance between anti-apoptotic and proapoptotic protein expression, inducing cell death. 19, 20 Although HAX-1 has been suggested to be an anti-apoptotic protein, its participation in controlling this balance is virtually unknown in the heart. To address this question, we assessed the expression levels of HAX-1 after 30 minutes of coronary artery ligation, followed by 24 hours of reperfusion. There was a decrease in HAX-1 expression ( Figure 1A ), which also was confirmed in isolated hearts, subjected to 40 minutes of global no-flow ischemia, followed by 60 minutes of reperfusion ( Figure 1B) . The reduction was not attributable to changes in HAX-1 mRNA (Online Figure II) , suggesting a posttranslational regulation of HAX-1 levels during I/R. These findings suggest that decreases in HAX-1 expression may contribute to tissue death after I/R injury.
To examine whether restoring HAX-1 levels can confer protection after I/R, mice with cardiac-specific HAX-1 overexpression (HAX-1 overexpression: 2.5-fold) 18 along with isogenic wild-type (WT) mice were subjected to in vivo coronary artery ligation. The ratio of infarct to risk region was significantly reduced from 23.5%±7% in WT hearts, typical for this mouse strain, 21, 22 to 16%±3% in HAX-1 overexpressions (Figure 2A ), whereas the region at risk was not significantly different between these 2 groups (HAX-1 overexpression, 58%±4.3%; WT, 59%±3.6%; P>0.05). Protection elicited by HAX-1 overexpression also was confirmed by a reduction in plasma troponin I levels ( Figure 2B ). To examine whether the reduction in infarct size by increased HAX-1 expression was related to inhibition of apoptotic events, we measured the extent of DNA fragmentation. HAX-1 overexpressing hearts showed significantly attenuated DNA fragmentation compared to WT hearts ( Figure 2C ). This finding was further supported by reduced caspase-3 activity in HAX-1 overexpression ( Figure 2D ), demonstrating the anti-apoptotic role of cardiac HAX-1 in vivo.
To further delineate the cardioprotective mechanisms associated with HAX-1 in the absence of neurohormonal factors, isolated hearts were subjected to ex vivo I/R injury using the Langendorff perfusion system. Interestingly, the decreased contractility previously observed in isolated cardiomyocytes by HAX-1 overexpression 18 did not translate to decreased function in the intact heart ( Figure 3A and 3B ). This apparent discrepancy also was previously noted with studies of Bcl-2 [23] [24] [25] [26] and other mouse models, 27, 28 indicating that cardiomyocyte contractility is not the sole determinant but a number of additional factors, such as sheer force on the sarcolemma, cell-cell/matrix interactions, and the endothelium, influence whole-heart performance. After ischemia, functional recovery, measured by rates of contraction (+dP/dt) and relaxation (−dP/dt), was significantly increased in HAX-1 overexpressing hearts ( Figure 3A and 3B), leading to enhanced left ventricular developed pressure and lower left ventricular diastolic pressure (Online Figure III) . This improvement in contractility was accompanied with a 30% reduction in myocardial infarct size, compared with WT hearts ( Figure 3C ). Similar to in vivo myocardial infarction studies, the protective effect was related to inhibition of apoptosis, in which overexpression of HAX-1 significantly attenuated the increases in DNA fragmentation, terminal dUTP nick-end labeled nuclei, and caspase-3 activity to 70%, 77%, and 35% of WT values, respectively ( Figure 3D and 3E, Online Figure IV) . Thus, both in vivo and ex vivo studies suggest that restoring HAX-1 levels after I/R injury may prevent cell death and improve heart contractile recovery.
HAX-1 Attenuates ER Stress Response Through Specific Inhibition of IRE-1
During I/R injury, proper protein folding in the ER/SR compartment is disturbed. The accumulation of misfolded peptides can elicit ER stress signaling response (IRE-1, PERK, and ATF-6) that is capable of inducing apoptosis through caspase activation and increased pro-apoptotic protein expression. 7, 8 Although HAX-1 shows ER/SR localization and regulates SR calcium cycling in cardiomyocytes, 18 its involvement in ER stress response is unknown. To address this, we examined the ER stress response in our HAX-1 overexpression model after I/R injury. Under basal conditions, there was no significant difference in the expression levels of the ER stress-induced chaperones, glucose-regulated protein 94, and protein disulfide isomerase, as well as the pro-apoptotic transcription factor C/EBP homologous protein between WT and HAX-1 overexpressing hearts ( Figure 4 ). After I/R injury, the expression levels of these players were increased in both groups, but the increases in HAX-1 overexpression hearts were significantly lower compared with WT hearts (Figure 4 ). Furthermore, activation of caspase-12, an ER stress-associated caspase, was significantly attenuated by HAX-1. These findings suggest that the anti-cell death effect of HAX-1 is associated with reduction of pro-apoptotic gene expression and caspase activation that are coupled with ER stress response (Online Figure I) .
Because caspase-12 is a known substrate for calpain and inhibition of calpain has been shown to attenuate ER stressmediated apoptosis, 29 we examined the calpain activity. There were no differences between HAX-1 overexpression and WT hearts after ischemic injury ( Figure 5A ). This suggests that the reduced caspase-12 activity is regulated by a calpain-independent mechanism. Processing of caspase-12 and initiation of the caspase cascade may be facilitated by autophosphorylation and activation of IRE-1, 1 of the 3 canonical ER stress sensors. 13, 30 To test this hypothesis, we examined the IRE-1 phosphorylation status and found a 50% decrease in HAX-1 overexpression hearts after I/R injury (Online Figure V) . The inhibition of IRE-1 function by HAX-1 also was confirmed by its decreased endoribonuclease activity, measured by splicing of the full-length xbp-1 transcript ( Figure 5B ). Processing of the xbp-1 transcript allows translation of stable XBP-1 protein, a transcription factor that regulates the expression of ER stress-related genes. Assessment of XBP-1 protein levels indicated parallel alterations as the spliced xbp-1 transcript (data not shown). Therefore, reduction of IRE-1 activity and the associated XBP-1 levels appear consistent with the attenuated expression of glucose-regulated protein 94, protein disulfide isomerase, and C/EBP homologous protein in HAX-1 overexpression hearts after reperfusion injury (Online Figure I) . Surprisingly, there was no significant attenuation of the other two ER stress signaling pathways, PERK and ATF-6, by HAX-1. Activation of PERK, measured by phosphorylation of the eukaryotic translation initiation factor 2-alpha, was elevated to similar levels in both models after I/R ( Figure 5C ). In addition, the ER transmembrane transcriptional factor ATF-6, which requires proteolytic cleavage for activation to translocate to the nucleus and upregulate ER stress-induced genes, including the primary full-length xbp-1 transcript, 31 was increased to similar levels in both groups, as indicated by ATF-6 cleavage ( Figure 5D ). This finding also was supported by the lack of attenuated expression of total (full-length + spliced) xbp-1 transcript in the HAX-1 overexpression group (Online Figure VI) . Thus, HAX-1 appears to specifically regulate the IRE-1 pathway without affecting the other 2 ER stress pathways (Online Figure I) . To examine whether IRE-1 inhibition can confer protection during ER stress, isolated WT cardiomyocytes were treated with brefeldin A to induce ER stress, in the absence or Figure 3 . Overexpression of HAX-1 improves cardiac contractile recovery after ischemia-reperfusion (I/R) by decreasing apoptosis. Isolated wild-type (WT) and HAX-1 overexpressing hearts were subjected to either 100 minutes of perfusion (basal) or 40 minutes of no-flow ischemia, followed by 60 minutes of reperfusion (I/R). A and B, Rates of contraction and relaxation (±dP/dt, mmHg/ min; n=6 for WT and 8 for HAX-1 overexpression). C, Representative images of triphenyl tetrazolium chloride staining and quantification of infarct size in WT and HAX-1 overexpressing hearts after I/R injury (n=6 hearts for each group). D, DNA fragmentation expressed as fold over WT basal (n=4 hearts for each group). E, Caspase 3 activity expressed as fold increase over WT basal (n=6 hearts for each group). *P<0.05, compared with WT basal.
# P<0.05, compared with WT I/R. Data are presented as mean±SEM. presence of the IRE-1 inhibitor, irestatin. Induction of apoptosis, associated with brefeldin A and measured by annexin V staining (Online Figure VII) , was blocked by irestatin treatment (Online Figures VIII and IX) . These findings indicate that IRE-1 inhibition promotes myocyte survival under ER stress conditions. Overexpression of HAX-1 completely abrogated apoptosis, similar to IRE-1 inhibition (Online Figure  IX) , further supporting the role of HAX-1 in prevention of cell death induced by ER stress. Additionally, inhibition of IRE-1 in isolated WT cardiomyocytes, subjected to simulated I/R, 32 attenuated apoptosis ( Figure 5E ), demonstrating that IRE-1 inhibition is protective in cardiomyocytes under this condition. More importantly, HAX-1 overexpressing cardiomyocytes, which exhibited better survival than WT cardiomyocytes, did not respond to irestatin treatment ( Figure 5E ). These findings for brefeldin A and simulated I/R studies suggest that IRE-1 inhibition is one of the mechanisms underlying cardioprotection by HAX-1.
Reduction of HAX-1 Level Exacerbates Cardiac I/R Injury
To test whether loss of HAX-1 contributes to cardiac injury, we subjected the HAX-1 heterozygous-deficient mice (HAX-1 +/− ) to I/R. Reduced HAX-1 expression (by 64%) 18 was associated with increased infarct size ( Figure 6A) and plasma troponin I level (Online Figure X) after in vivo I/R injury. Furthermore, exacerbated cardiac contractile dysfunction was observed in HAX-1 +/− hearts with 60% and 47% recovery of +dP/dt and -dP/dt parameters, respectively, when compared with WT hearts after ex vivo I/R (Online Figure XI) . These findings indicate the importance of HAX-1 in preserving contractile function on I/R injury.
Consistent with compromised cardiac function, the extent of apoptosis was elevated after ex vivo I/R in HAX-1 heterozygous hearts, as indicated by significant increases in DNA fragmentation, terminal dUTP nick-end labeled nuclei, and caspase-3 activity compared with WT hearts ( Figure 6B and 6C, Online Figure XII) . The elevated apoptosis was related to exacerbated ER stress response, associated with increased expression of ER stress markers (glucose-regulated protein 94 and cleaved caspase-12; Figure 6D ). The IRE-1 activity also was enhanced as demonstrated by significant increases in XBP-1 protein expression ( Figure 6D ). Together with the HAX-1 overexpression studies, our findings suggest that HAX-1 prevents ER stress-induced apoptotic responses through inhibition of IRE-1 activity.
HAX-1 Regulates IRE-1 Activity Through Hsp90
Previous studies in COS-7 and pancreatic tumor cell lines reported that IRE-1 binds Hsp90, and this promotes its stable conformation or activity. 33 Thus, we examined the expression levels of Hsp90 in WT and HAX-1 overexpression hearts before and after I/R. However, there were no differences among these groups (Online Figures XIII and XIV) . It then was determined whether HAX-1 may disturb the IRE-1/ Hsp90 interaction, resulting in decreased IRE-1 activity. Immunoprecipitations, using the HAX-1 antibody as bait, revealed that Hsp90 was pulled down from both WT and HAX-1 overexpressing hearts (Online Figure XV) . This association also was observed in reciprocal experiments, using the Hsp90 
. Overexpression of HAX-1 attenuates endoplasmic reticulum (ER) stress after ex vivo ischemia-reperfusion (I/R).
Isolated wild-type (WT) and HAX-1 overexpressing hearts were subjected to either 100 minutes of perfusion (basal) or 40 minutes of no-flow ischemia, followed by 60 minutes of reperfusion (I/R). A, Representative immunoblot for glucose-regulated protein 94 (GRP94), protein disulfide isomerase (PDI), cleaved caspase-12, and C/EBP homologous protein (CHOP) expression levels. GAPDH was used as control. B, Quantification of GRP94, PDI, cleaved caspase-12, and CHOP expression levels (n=4-6 hearts). *P<0.05, compared with WT basal. antibody as bait ( Figure 7A ). Importantly, overexpression of HAX-1 enhanced the HAX-1/Hsp90 association ( Figure 7A ), whereas the Hsp90/IRE-1 interaction was reduced compared with WT hearts (Figure 7A and 7B) . To determine the binding domains of HAX-1 or IRE-1 on Hsp90, recombinant proteins were used in in vitro binding assays. Both HAX-1 and the cytosolic domain of IRE-1 33 directly interacted with the N-terminal fragment (amino acid 1-199) of Hsp90 ( Figure  7C ). The binding of these proteins on Hsp90 appeared to be competitive, as demonstrated by recombinant protein binding enzyme-linked immunosorbent assays. The interaction of HAX-1 with Hsp90 gradually decreased with increasing amounts of the IRE-1 cytosolic fragment. The same trend also was observed for IRE-1/Hsp90 interaction, when the levels of HAX-1 were increased ( Figure 7D and 7E ). These findings suggest that overexpression of HAX-1 in the heart destabilizes IRE-1 activity by displacing it from Hsp90.
To further examine whether HAX-1 regulates IRE-1 activity through Hsp90, we used isolated rat cardiomyocytes and induced ER stress pharmacologically, whereas HAX-1 expression or Hsp90 activity was manipulated. Brefeldin A administration (Online Figure XVI) in GFP-infected cardiomyocytes resulted in ≈2.7-fold upregulation of spliced xbp-1 transcript levels, reflecting increased IRE-1 activity. This increase was attenuated to a similar extent by overexpression of either HAX-1 or Hsp90 inhibition by 17-N-allylamino-17-demethoxygeldanamycin (0.1 μmol/L). When HAX-1 overexpressing cardiomyocytes were treated with Hsp90 inhibitors, there was no additional attenuation compared with either treatment alone ( Figure 7F ), indicating that HAX-1 can no longer inhibit IRE-1 function in the face of Hsp90 inhibition. This finding was further supported by studies in isolated mouse cardiomyocytes, where Hsp90 inhibition abolished the difference between WT and HAX-1 overexpression cells in ER stress-induced apoptosis. Furthermore, Hsp90 inhibition also abolished the enhancement of brefeldin A-induced apoptosis in HAX-1 +/-cardiomyocytes (Online Figure XVII) . Because HAX-1 expression was reduced after I/R ( Figure  1A and 1B), accompanied with enhanced IRE-1 activity ( Figure 5B) , coimmunoprecipitation experiments were performed to further address the role of HAX-1 in the formation of the Hsp90-IRE-1 complex. Using the Hsp90 antibody as bait, there was a decrease in the HAX-1 levels associated with Hsp90, which was accompanied with an enhanced Hsp90-IRE-1 association in WT hearts after I/R. This increase also was observed in reciprocal experiments using the IRE-1 antibody (Online Figure XVIII) . Thus, the loss of HAX-1 during I/R may allow Hsp90 to stabilize IRE-1 activity and promote the ER stress response.
PLN Facilitates Recruitment of HAX-1/Hsp90 to SERCA
The studies indicate that Hsp90 may get recruited away from the IRE-1 signaling complex in the presence of HAX-1. Because HAX-1 has been reported to interact with the PLN/ SERCA complex, 18 we examined the potential association of Figure 5 . HAX-1 specifically inhibits the IRE-1 pathway. Wild-type (WT) and HAX-1 overexpressing hearts subjected to no-flow ischemia followed by reperfusion (ischemia-reperfusion [I/R]) in Figure 4 were processed for the examination of endoplasmic reticulum (ER) stress signaling pathways. A, Calpain activity expressed as fold over WT basal (n=4-6 hearts). B, Quantification of spliced xbp1 mRNA levels using real-time polymerase chain reaction. GAPDH was used as control (n=3 for basal, n=4-6 for I/R). C and D, Quantification of phosphorylated eukaryotic translation initiation factor 2-alpha (eIf2α)/total-eIf2α and cleaved ATF-6 expression. GAPDH was used as control (n=4-6 hearts). E, Apoptosis, measured by annexin V staining, of isolated cardiomyocytes after simulated ischemia/reperfusion procedure (simulated I/R), with or without Irestatin (n=16 hearts for WT and 13 for HAX-1 overexpression in each treatment group). *P<0.05, compared with WT basal or control. Hsp90 with PLN/SERCA using a GST-recombinant protein pull-down assay. GST-Hsp90 pulled-down HAX-1, PLN, and SERCA, as revealed by Western blot analysis ( Figure 8A ). This SERCA/PLN/Hsp90 association also was observed in GST-PLN pull-down samples (Online Figure XIX) . Furthermore, immunoprecipitations from WT or HAX-1 overexpressing hearts, using the Hsp90 as bait, confirmed the presence of HAX-1, PLN, and SERCA in the precipitated protein complex ( Figure 8B) . Accordingly, immunofluorescence studies showed that Hsp90 colocalizes with SERCA in the HAX-1 overexpressing cardiomyocytes (Online Figure XX) . Control experiments using HAX-1 as bait in PLN knockout cardiac homogenates indicated reduced Hsp90 levels in coimmunoprecipitates ( Figure 8C ). These findings were also confirmed using the Hsp90 antibody as bait in PLN knockout hearts ( Figure 8D ). Thus, the protective effects of HAX-1 in the stressed heart may involve the formation of a multimeric protein complex of Hsp90/HAX-1/PLN/SERCA.
Hsp90 and HAX-1 Inhibition of SR Ca Cycling
We previously reported that HAX-1 overexpression augments PLN inhibition of SERCA and attenuates calcium cycling.
18
Because HAX-1 interacts with Hsp90, we sought to determine whether this chaperone protein participates in HAX-1 inhibition. Thus, we examined the calcium transient kinetics in isolated WT and HAX-1 overexpressing cardiomyocytes in the absence and presence of the Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin. The administration of 17-N-allylamino-17-demethoxygeldanamycin (0.1 μmol/L) had no significant effect on WT cardiomyocytes. However, it reversed the HAX-1 inhibitory effects by enhancing the calcium transient amplitude ( Figure 8E ) and by abbreviating the time constant of calcium decay ( Figure 8F ) in HAX-1 overexpression cardiomyocytes. The stimulated parameters in treated HAX-1 overexpressing cells were similar to those in WT hearts. These findings suggest a potential regulatory role of Hsp90 in calcium cycling.
Discussion
In the current study, we demonstrate for the first time that HAX-1 interacts with Hsp90, mediating cardioprotection through specific attenuation of IRE-1 activity in the ER/SR. A previous study in pancreatic tumor cell lines showed that Hsp90 is a binding partner of IRE-1 and promotes its activity. 33 A similar mechanism also appears to operate in the heart and overexpression of HAX-1 recruits Hsp90 to PLN/ SERCA, resulting in decreased IRE-1 activity and attenuation of apoptosis (Online Figure I) .
Since its discovery in 1997, HAX-1 has been suggested to be anti-apoptotic.
14 Ablation of HAX-1 led to excessive neuronal cell death, which was caused by accumulation of Bax, resulting from inadequate maturation of HtrA serine peptidase 2, a mitochondrial serine protease that is released to cytosol on maturation and that promotes the activity of the inhibitor of apoptosis proteins. 17 However, because the cellular distribution of HAX-1 differs in various cell types, 34 it is important to note that survival mechanisms mediated by HAX-1 may be different in the heart, where it shows significant ER/SR localization. 18 This notion is supported by the findings that redistributing HAX-1 to ER through PLN coexpression enhances survival in HEK293 cells. 35, 36 In this regard, the present study provides the first evidence that the ER/SR-localized HAX-1 can modulate apoptotic signaling through the ER stress response pathways.
Growing evidence supports the significance of ER stress signaling pathways in I/R injury, because they impact both survival and death decisions. HAX-1 plays a critical role in fine-tuning the ER stress response through indirect but specific inhibition of IRE-1 pathway, which has been suggested to serve as the switch to death signaling, 37 because of its ability to activate caspase-12, 13 c-Jun N-terminal kinase signaling, 11 and pro-apoptotic gene expression. 38 This beneficial effect of IRE-1 inhibition also is demonstrated by improved cardiomyocyte survival in simulated I/R studies. Notably, HAX-1 does not inhibit the other 2 ER response-elicited pathways, PERK and ATF-6. This is particularly important because inhibition of the ATF-6 ER stress response pathway was shown to be detrimental to the heart in ischemic injury. 10 Altogether, HAX-1 is able to ameliorate cell-death signaling by limiting caspase-12 initiation and pro-apoptotic protein expression, without complete abrogation of the chaperone protein induction (ATF-6) and global protein synthesis suppression (PERK). Thus, HAX-1 may be beneficial in ischemic injury by preventing cell death, because it widens the window for cardiomyocytes to rectify contractile dysfunction. The inhibitory effects of HAX-1 on IRE-1 appear to be mediated through its interaction with Hsp90, an abundant cytosolic chaperone protein that can be recruited to virtually every cellular compartment and facilitate proper folding, posttranslational modification, trafficking, and degradation of a great array of client proteins. 39 Cardiac Hsp90 has been generally considered to be protective, because the Hsp90 inhibitor increases cardiomyocyte apoptosis through reducing pro-survival Akt signaling 40 and enhancing the activity of pro-apoptotic p38α, 41 a member of mitogenactivated protein kinases. In isolated hearts, Hsp90 also has been shown to guide the transclocation of protein kinase Cε to the mitochondria and to reduce injury after I/R insults. 42 In endothelium, Hsp90 plays an integral role in endothelial nitric oxide synthase signaling, 43 a pro-survival mechanism, in activation in cardiomyocytes. 3 The present study shows for the first time that Hsp90 also may mediate some of its cardioprotective effects at the ER/SR level. This regulation is facilitated by HAX-1, which sequesters Hsp90 to the PLN/ SERCA calcium transport complex.
Substrate specificity of Hsp90 under various cellular conditions is facilitated by its co-chaperone proteins. 44 When a particular cellular pathway is activated, a co-chaperone protein in the signaling complex can recruit or alter the activity of Hsp90, affecting its substrate regulation. 39, 44 The current study suggests that HAX-1 may be a novel co-chaperone protein for Hsp90. Increased HAX-1 expression recruits Hsp90 to the PLN/SERCA, shifting the apparent substrate specificity of Hsp90 and reducing apoptosis induced from the ER/SR. This is especially important under I/R, when the HAX-1 levels get reduced and favor increased association of Hsp90 with IRE-1 that promotes the stress response. Thus, the HAX-1/ Hsp90 complex may serve as a brake on cell-death signaling. However, the regulatory effects of HAX-1 on Hsp90 may go beyond the level of ER/SR, because HAX-1 has been shown to interact with an array of proteins with different subcellular localizations, including mitochondria in various tissues. 34, 45 Furthermore, Hsp90 appears to facilitate the inhibitory effect of HAX-1 on SR calcium uptake, 18, 35 which may provide another mechanism of cardioprotection. Pretreatment with a SERCA inhibitor to reduce SR calcium content previously was shown to be protective in I/R injury, 46, 47 possibly by preventing mitochondria calcium overload. 3, 48 The current study indicates that Hsp90 may modulate the inhibitory function of HAX-1 on calcium cycling and suggests that regulation of SR calcium transport may occur through a putative quaternary protein complex composed of SERCA/PLN/HAX-1/Hsp90. Moreover, given the role of PLN in maintaining HAX-1 at the ER/SR, 36 it is interesting to propose that the detrimental effects of PLN deficiency in I/R injury 49 may not be simply mediated by calcium dysregulation, because enhancing SR calcium uptake by either overexpressing SERCA1a 50 or active protein phosphatase 1 inhibitor-1, a repressor of PLN activity, 21 showed improved function and reduced injury after ischemic insults. The removal of PLN may disrupt the compartmentalization of the HAX-1/Hsp90 complex and disinhibit the apoptotic signaling through the ER pathways, affecting life-or-death decisions in I/R injury.
In summary, the current study is the first to demonstrate the interaction of HAX-1 with Hsp90 and the role of this complex in protection against IRE-1 activation during cardiac I/R injury. Our findings not only suggest an important gate-keeping role of HAX-1 in apoptosis but also have wide-ranging implications in multiple tissues and cellular pathways, given the ubiquitous and abundant nature of Hsp90. 
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Dr Kranias is a scientific founder of Nanocor. GST pulldown assays were performed using mouse cardiac homogenates and GST-Hsp90 or GST recombinant proteins. The associations with SERCA2, HAX-1, and PLN were determined by Western blot analysis with appropriate antibodies. B, Centrifuged homogenates from wild-type (WT) and HAX-1 overexpression hearts were subjected to coimmunoprecipitation using the Hsp90 antibody. Five independent experiments were performed. C and D, Same procedure (as B) was performed with WT and PLN knockout (PLNKO) homogenates using HAX-1 and Hsp90 antibodies. Five independent experiments were performed. E and F, Calcium transient peak (n=47-73 cells from 9 WT hearts and 8 HAX-1 overexpressing hearts) and time constant for calcium decay (Tau, n=16-30 cells from 4 hearts in each group) in isolated WT and HAX-1 overexpressing myocytes with or without the administration of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG). *P<0.05, compared with WT basal. Data are presented as mean±standard error of the mean.
